#AUA24 Nimrod Barashi, M.D. Variation in PCa Genomic Subtypes Across PI-RADS Scores and Race UroToday.com Decipher by Veracyte

📍n=760, 81% non-AA, 17% AA
📍Decipher: low (53%), interm (18%), high (29%)
📍PI-RADS 3-5 vs 1-2: more luminal proliferating (31% vs 17%, p=0.004) and luminal B (45%…

Avelumab 1st-line maintenance for adv #UrothelialCarcinoma : Long-term outcomes from #JAVELIN Bladder 100 in subgroups defined by 1st-line chemotherapy regimen and analysis of OS from start of 1st-line chemotherapy Shilpa Gupta > bit.ly/4b6tbK8 Zach Klaassen #AUA24

(2/2) #AUA24 Todd 〽️ Morgan, MD - Dev/Val of a MMAI-derived dig path-based biomarker predicting mets for RP pts w/ BCR in RTOG trials UroToday.com ArteraAI

10-yr cumul risk mets, RT vs RT+HT:
📍HR: 41% vs 18% (HR 2.16, 95%CI 1.25–3.72)
📍LR: 10% vs 8% (HR 1.21, 95%CI 0.57-2.58)

(1/2) #AUA24 Todd 〽️ Morgan, MD - Dev/Val of a MMAI-derived dig path-based biomarker predicting mets for RP pts w/ BCR in RTOG trials UroToday.com ArteraAI

📍Val set: 212 (40%) HR, 321 (60%) LR
📍10-yr cumul incid DM rate: 27.0% HR vs 8.7% LR (p<0.001):
📍Model assoc w/ LT outcomes

#AUA24 Shilpa Gupta Avel 1L maintenance for aUC: Long-term outcomes from JAVELIN Bladder 100 in subgroups -- 1L chemo regimen and analysis of OS from start of 1L chemo UroToday.com

📍Overall pop: mOS from start 1L chemo - 29.7 mos for Avel + BSC vs 20.5 mos for BSC alone (HR 0.77,…

#AUA24 At the SUO meeting during AUA Jonathan Rosenberg MD discussed how to incorporate ENFORTUMAB with or without PEMBRO into our clinical practice. The key points from his talk were:

🚩EV+Pembro transforming UC care
🚩Toxicity can be significant and may prevent curative therapy in a…

#AUA24 In a rapid-fire debate at the SUO meeting during AUA Dr. Hooman Djaladat and Phillip Pierorazio presented crucial arguments both for and against LND for UTUC. Here are the highlights:
🚩No level 1 evidence (3 guidelines endorsing LND)
🚩More accurate risk stratification,…

#AUA24 Joseph Shirk delivered a comprehensive review on renal imaging for active surveillance at the SUO meeting during AUA. The highlights were:

🚩Conventional imaging still the gold standard for AS
🚩Other modalities (CEUS, SPECT/CT) may have a role in certain patient cohorts…

#AUA24 Leslie Ballas discussed the future of radiation in treating localized and oligometastatic RCC at the SUO meeting at AUA. Here are the key take-home messages:

🚩In carefully selected pts with oligometastatic RCC SABR may delay the need for systemic treatment
🚩Fastrack II…

#AUA24 . SamWashUro delved into the dissemination and availability of minimally invasive treatments for underserved populations, presenting compelling arguments in favor of continued MIS dissemination. He also discussed strategies for improvement. Here are the highlights from his…

Does Decipher have value in NCCN HR pts based no PSA level alone (i.e., GG1-3 w/ PSA >20)?
🔷Decipher score strongly associated with risk of mets (high vs low: sHR=6.8; int vs low: SHR=2)
🔷PSA not sig associated with risk of mets (>20 vs ≤20: sHR 1.2, p=0.81)
📌Could use…

Journal of Urology Lecture: Empowering communities: fostering #ProstateCancer awareness and resilience among men of color. Presentation by Quoc-Dien Trinh, MD, MBA Brigham and Women's Faulkner Hospital. #AUA24 written coverage by Rashid K. Sayyid University of Toronto > bit.ly/4bprwis

#AUA24 @Sonpavde shared the results of a secondary analysis from the phase 3 CheckMate 901 trial, comparing NIVO +GC vs. GC alone in patients who responded to treatment:

🚩 OS (HR 0.78; 95% CI, 0.63–0.96; p=0.0171) significantly improved with NIVO+GC vs GC
🚩 ORR 57.6% vs 43.1%…

#AUA24 Chiara Mercinelli presented the results of the phase 2 NURE-Combo study: Neoadjuvant NIVO + nab-paclitaxel (ABX) followed by post-surgical adjuvant NIVO in pts with MIBC:

🚩31 pts enrolled, 39% had cT3-4 disease, 45% cT2 and 6.4% N1. 48.4% had variant histology
🚩 12 pts…

A phase II trial of intravesical gemcitabine and docetaxel (GEMDOCE) in the treatment of BCG-naïve non-muscle invasive #UrothelialCarcinoma of the #Bladder . Presented by Andrew Gabrielson The Johns Hopkins Brady Urological Institute. #AAU24 written coverage by Rashid K. Sayyid University of Toronto > bit.ly/3Qvwna6 Amer. Urol. Assn.

Descriptive tumor characteristics of 992 consecutive Patients Who Underwent Staging with PSMA PET/CT Before Radical Prostatectomy. Presentation by Felix Preisser, MD UKE Hamburg. #AUA24 written coverage by Julian Chavarriaga University of Toronto > bit.ly/3WqgR2M Amer. Urol. Assn.

Comparison of BCG to gemcitabine/docetaxel in the intermediate risk group composed mostly of TaHG. Presented by Reuben Ben-David Icahn School of Medicine at Mount Sinai. #AUA24 written coverage by Rashid K. Sayyid University of Toronto > bit.ly/4a0NreZ Amer. Urol. Assn.

Impact of 18F-DCFPyL on accuracy of mpMRI in men with low and intermediate-risk #ProstateCancer : Interim analysis of a phase II diagnostic trial. Presentation by Marcelo Bigarella, MD UW–Madison. #AUA24 written coverage by Rashid K. Sayyid University of Toronto > bit.ly/4a7Z2Jc Amer. Urol. Assn.

Clinical characterization of #mHSPC based on real-world data: Can randomized #ClinicalTrials be more reliable? Data from the European Network of Excellence for Big Data in #ProstateCancer #PIONEER Rossella Nicoletti > bit.ly/3Wlq0K6 Prostate PIONEER Julian Chavarriaga #AUA24

Development of a prediction model of survival amongst patients with #mHSPC using #BigData : interim results from Prostate PIONEER. Presentation by Rossella Nicoletti Azienda Ospedaliero-Universitaria Careggi. #AUA24 written coverage by Julian Chavarriaga University of Toronto > bit.ly/4dsajXG Amer. Urol. Assn.